Naoko Takebe to ErbB Receptors
This is a "connection" page, showing publications Naoko Takebe has written about ErbB Receptors.
Connection Strength
0.128
-
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 03 15; 27(6):1604-1611.
Score: 0.045
-
Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs. 2018 06; 36(3):442-450.
Score: 0.036
-
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst. 2013 Jan 02; 105(1):11-24.
Score: 0.026
-
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15.
Score: 0.022